# Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

> **NCT06760260** · EARLY_PHASE1 · RECRUITING · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 7 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Human Derived anti-CI135 CAR-T Injection

## Key facts

- **NCT ID:** NCT06760260
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760260, "Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06760260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*